Additional data for the BCMA-targeting bispecific antibody CC-93269 for multiple myeloma (Also see "Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience" - Scrip, 19 December, 2019.)

Clinical data that will enable next-step decisions for multiple Cereblon modulators for myeloma and acute myeloid leukemia (AML)

The first investigational new drug (IND) application filing for the company’s protein degradation platform

Additional early clinical data for the LAG3-targeting antibody relatlimab in solid tumors

Other noteworthy programs: BMS-986177, targeting Factor XIa in Phase II for thrombotic diseases; pegbelfermin, a long-acting variant of fibroblast growth factor 21 (FGF21) in Phase II for non-alcoholic steatohepatitis (NASH); BMS-986202, a lysophosphatidic acid receptor 1 (LPA1) antagonist in Phase I for pulmonary fibrosis; Jun N-terminal kinase (JNK) inhibitor CC-90001 in Phase II for idiopathic pulmonary fibrosis (IPF) and NASH; and a Bruton’s tyrosine kinase (BTK) inhibitor in Phase II for rheumatoid arthritis

BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says

More from Deals

More from Business